It's a pity that the person who wrote this article has his facts slightly wrong. At present Campath is not expected to be given for life. At the moment recipients are treated twice over 2 years as a matter of course and then are only treated as and when the need presents itself.
Whilst ITP is a serious and potentially life threatening condition it is easily spotted and treated. After the death on the trial everyone who recieves Campath is monitored via monthly blood tests. This may seem onerous but I would rather do that than have monthly infusions (Tysabri) or thrice weekly injections (rebif). In addition the efficacy (which is what really matters to me) blows those two out of the water.
Lets not forget that 3 people died as a result of PML from Tysabri (A far more serious condition than ITP) Yet Tysabri is back on the market.
Whilst Campath will not be for everyone, for those whos MS is refactory to other treatments it is the best hope we have seen. I for one sincerely hope that the regulatory authorities take an objective view on this.
Everyone who I have spoken to who is connected to the trials expects Campath to be approved for MS in the not too distant future.
Do not go gentle into that good night. Rage, rage against the dying of the light.